US 8148079

I'll search for authoritative information on this patent.

Let me search for litigation/docket information and the exact independent claim text.

Let me retrieve the exact independent claim text.

US Patent 8,148,079 — Analyst Summary

Search scope note: I ran targeted web searches against public patent databases (Google Patents, Justia Patents, INPI, DrugPatentWatch) and for Federal Circuit / PTAB docket activity. I did not have direct PACER/CourtListener access, so my litigation findings rest on the absence of any indexed hit rather than a definitive docket-level negative. See "Litigation / CAFC 2026" below.

---

Bibliographic Data (as indexed)

Note: Google Patents lists the prior-art date as 2006-08-09, consistent with the JP priority filing.

---

Abstract (as published, verbatim substance)

A method of producing a PCR amplification product that suppresses the effect of precipitate, turbidity, etc. derived from a whole blood sample on detection of amplified nucleic acid by an optical unit. The amplification product complementary to a target nucleic acid in the whole blood sample is produced by PCR under the condition that the ratio of whole blood sample in the PCR reaction solution is 0.1 to 0.9% by volume or 0.01 to 1.8 g/L in terms of hemoglobin content. With such conditions, even with an untreated whole blood sample, monitoring of the amplification product by the optical unit is possible while suppressing precipitate/turbidity effects.

⚠️ Internal numeric inconsistency worth flagging (literal reading): the abstract states "0.1 to 0.9% by volume" and "0.01 to 1.8 g/L," whereas the summary-of-invention and definitions passages in the same document state "about 0.01 to 0.9% by volume" and, in one place, "about 0.01 to 1.5 g/L in term of Hb content," while another place says "0.01 to 1.8 g/L." I am reporting these as they appear rather than harmonizing them.

---

Plain-Language Overview of the Independent Claims

The claim set runs to 26 claims. The granted claim 1 is the analysis claim (the pre-grant publication's claim 1 was the producing claim — see caveat below).

Claim 1 — Method of analyzing an amplification product (qualitative or quantitative)
You run PCR to make an amplification product complementary to a target nucleic acid in a whole blood sample, where the whole blood makes up 0.01–0.9% by volume of the PCR reaction solution, then you detect the amplification product with an optical unit (e.g., a fluorometer). Essentially: a real-time/optically-read PCR analysis method defined by a specific whole-blood dilution window that keeps the reaction clear enough to read.

Claim 18 — Method of analyzing a target nucleic acid (quantitative)
Three steps: (A) prepare the PCR amplification product from whole blood with the ratio again limited to 0.01–0.9% by volume; (B) quantitatively analyze the amplification product by optical detection; and (C) quantify the target nucleic acid in the whole blood by determining the number of PCR cycles at which the amplification product reaches a specified quantity — i.e., a Ct/real-time-quantification claim.

Claim 23 — Method of suppressing the effect of precipitate and/or turbidity in PCR of a whole blood sample
A purpose-framed independent claim: prepare the amplification product from whole blood by PCR while limiting the whole blood ratio in the PCR reaction solution to 0.01–0.9% by volume. The "suppression of precipitate/turbidity" is recited as the effect of the limiting step rather than as a separate measuring step.

Claim 25 — unverified. The claim listing I retrieved shows claim 24 (Hb-content alternative depending from claim 1) and claim 26 (Hb-content alternative depending from claim 23), with the text of claim 25 truncated to "25." in the source snippet. I could not retrieve claim 25's text, so I will not characterize it. It is plausibly a parallel Hb-content dependent claim, but that is a guess and should not be relied upon.

Representative dependent claims (for context): albumin added to the PCR solution before PCR (0.1–1 wt%); heat treatment of the whole blood sample before PCR (80–99 °C; ≥30 s); use of a diluted sample (0.01–90% v/v whole blood in the diluent); DNA or RNA (via reverse transcription) target; ≥30 cycles; detection with time; fluorescence detection via intercalator, or via fluorescent substance/quencher/probe; Tm analysis.

⚠️ Claim-version caveat: The Justia pre-grant publication (US 2009/0269754 A1) lists claim 1 as "A method of producing an amplification product complementary to a target nucleic acid in a whole blood sample by PCR, wherein a ratio of the whole blood sample in a PCR reaction solution is in a range of 0.01 to 0.9% by volume." However, the dependent claims retrieved for the granted patent (e.g., "The method of analyzing an amplification product according to claim 1…") and the DrugPatentWatch claim listing for 8,148,079 both indicate that the granted claim 1 is the analyzing-method claim. That is consistent with amendment during prosecution, but I have not reviewed the file wrapper, so the exact granted wording of claim 1 should be confirmed against the USPTO PatentCenter/Patent Public Search text of the granted patent.

---

Technical Substance (building on the previously generated sections)

The disclosure and examples support the claimed window empirically: in Example 1 (β-globulin 408 bp amplicon, SYBR Green I intercalator), amplification was not observable fluorometrically at high whole-blood levels (≈2% v/v and above — attributed to light blocking by precipitate/turbidity), while fluorescence measurement was sufficient at ≤0.5% v/v whole blood. Example 2 showed added BSA (0.4 wt%) further raised signal; Example 3 showed a marked fluorescence increase at ≥0.2 wt% BSA in a heat-treated (95 °C/5 min), non-amplifying system. Examples 4–7 (amylin 105 bp amplicon, FAM/DABCYL probe, i-Cycler) showed pre-heating a diluted whole-blood sample lowered Ct by ~1.7–2.4 cycles (≈3.2–5.3× more initial template), with the effect present at ≥80 °C and ≥30 s. The stated advance is that no pre-PCR purification (pretreatment) or post-PCR purification (aftertreatment) is needed, and that optical/real-time monitoring — not just end-point electrophoresis — becomes possible.

Cited prior art includes Mercier et al. (Nucleic Acids Res.) and a paper on "PCR based diagnosis in the presence of 8% (v/v) blood," plus JP3727667B and the Non-Patent Documents 1–4 identified in the specification.

---

Litigation / CAFC 2026 Dockets

I found no Federal Circuit appeal, PTAB proceeding, or 2026 CAFC docket indexed to patent 8,148,079, and no litigation hits naming 8,148,079 as an asserted patent. Searches combining the patent number with "CAFC," "Federal Circuit," "litigation," and "Arkray" returned only patent-database and inventor-listing pages, not docket material.

Because I could not query PACER or a comprehensive docket aggregator directly, I cannot state definitively that no such proceeding exists. Treat this as "no evidence found," not as a verified negative. One tangential hit — a DrugPatentWatch "patent claims" page for 8,148,079 — is a claims-text database entry and does not by itself establish that the patent is Orange Book–listed or involved in Hatch-Waxman/BPCIA activity.

---

Confidence and Open Items

• High confidence: title, assignee, inventors, application/PCT/priority numbers, filing date, issue date, abstract substance, and the numerical ranges recited in the claims I retrieved.
• Medium confidence: the granted claim-1 text as the analyzing-method claim (corroborated by two independent sources indicating the granted independent claims are the analysis/quantification/suppression claims, but not confirmed against the grant document's own claims section, which was not present in the primary fetched text).
• Low confidence / unknown: the text of claim 25; the precise total number of independent claims (I can confirm at least three: 1, 18, 23); any unindexed litigation.
• Recommendation: verify the granted claims against USPTO PatentCenter for application 12/294,304, and check PACER/Docket Alarm/CourtListener directly for any 2026 activity before relying on the "no litigation" finding.

I'll research litigation involving US patent 8148079. Let me search multiple sources.

Let me search more targeted litigation databases.

Let me search litigation-specific databases directly.

Litigation Search Report — U.S. Patent No. 8,148,079

Patent identified: U.S. Patent No. 8,148,079 B2 ("Method of producing amplification product by PCR and usage thereof"), Application No. 12/294,304, filed 2007-08-07, granted 2012-04-03, priority date 2006-08-09, assignee Arkray, Inc., inventors Yuji Izumizawa and Satoshi Majima.

Finding: No litigation or post-grant proceedings located

Based on my searches, I found no evidence of any litigation or administrative challenge involving U.S. Patent No. 8,148,079. Specifically, I found:

What I checked and the limits of that check

I ran targeted searches for the exact number ("8148079," "8,148,079") across general web results and litigation-aggregator content that surfaced (Unified Patents Portal material, CourtListener/CourtListener-hosted RECAP documents, Docket Alarm, RPX Insight, drugpatentwatch). The only hits for the number were patent-data pages (Google Patents, Patent Leaderboard), which confirm bibliographic details but show no litigation history.

Important caveats on my confidence:

• This patent is a diagnostic/laboratory-method patent owned by a Japanese in-vitro-diagnostics manufacturer (Arkray), not a telecom/software patent. Such patents are far less commonly asserted, which is consistent with — but does not prove — an absence of suits.
• I could not directly query the Unified Patents litigation caselist, PACER, or CourtListener's API in this session; I relied on indexed search results. A negative search result across general indexes is not the same as a verified "zero" in PACER/Docket Alarm.
• I did not find any source affirmatively stating the patent has never been litigated.

Recommended verification steps before relying on this

To confirm a true negative, these should be run directly:

1. USPTO Patent Trial and Appeal Board (PTAB) — search Patent No. 8,148,079 in the PTAB End-to-End (PTAB E2E) / PatentCenter proceeding search.
2. PACER / CourtListener RECAP — search the exact patent number, not just the assignee.
3. Unified Patents Portal — https://portal.unifiedpatents.com/litigation/caselist (patent-number lookup).
4. Docket Alarm / RPX Insight — patent-level docket history.
5. USPTO Assignment/PatentCenter — confirm whether ownership (Arkray) has ever transferred, which often precedes assertion.

Bottom line

I cannot identify any plaintiff, defendant, jurisdiction, case number, filing date, or outcome for U.S. Patent No. 8,148,079, because no litigation record for this patent was found. If you need a legally reliable "no litigation" confirmation, the searches in the steps above should be performed directly against PACER and PTAB, since I could not exhaustively query those primary sources here.

Would you like me to draft search strings tailored to PACER/PTAB, or check the assignee name "Arkray" for any suits where this patent may have been among several asserted?

PTAB activity on US 8,148,079 — analyst report

Bottom line up front: there are no AIA trial proceedings on this patent. The structured USPTO ODP "PTAB proceedings on file" block returns a null set, and independent web searches for IPR/PGR/CBM petitions naming U.S. Patent No. 8,148,079 surfaced no PTAB filings, no Final Written Decisions, and no Federal Circuit appeals. Everything below is therefore a negative finding plus the defensive inference that follows from it — not a summary of proceedings, because there are none to summarize.

---

Proceedings overview

Total AIA trial proceedings on US 8,148,079: 0 — no IPRs, no PGRs, no CBMs, no derivations (breakdown by status is inapplicable: 0 active / 0 claims-invalidated / 0 claims-sustained / 0 settled / 0 institution-denied). The defensive posture this gives a defendant is "unhardened but also untested": the patent's claims stand exactly as they issued on 2012-04-03, with no PTAB estoppel, no cancellation, and no adjudicated claim construction to work from — but equally, no institution decision or FWD exists to tell you whether those claims are strong or paper-thin.

---

Proceedings

None. No proceeding numbers can be listed because no proceeding numbers exist. I will not invent them. Per the operating rules, the absence of any entry in the USPTO Open Data Portal block is the default and here it is confirmed by search.

What the record does show (non-PTAB), for context:

Source: https://patents.google.com/patent/US8148079/en

I found no PTAB E2E docket number, no FWD, no institution decision, no CAFC appeal docket, and no defensive-aggregator (e.g., Unified Patents) challenge in the chain. I cannot rule out a very recently filed, not-yet-publicly-indexed petition — PTAB petitions are typically not visible until the Board's public-information system posts them — so treat this as "clean as of the most recent ingest," not "clean forever."

---

Strategic summary

Claim status: all issued claims are UNTESTED. Because no PTAB trial ever reached a Final Written Decision, no claim of US 8,148,079 has been canceled, disclaimed, or held unpatentable at the Board. The claim set stands as granted. The commercial claim text surfaced via secondary sources shows an independent claim 1 directed to "A method of analyzing an amplification product… (A) preparing the amplification product complementary to a target nucleic acid in a whole blood sample by PCR, wherein a ratio of the whole blood sample in a PCR reaction solution is in a range of 0.01 to 0.9% by volume; and (B) detecting the amplification product by an optical unit," with dependents adding albumin (claims 2–4), pre-PCR heat treatment of the sample and its sub-parameters (claims 5–8), DNA vs. RNA/cDNA template (claims 9–10), ≥30 cycles (claim 11), time-resolved detection (claim 12), and fluorescence/optical-unit/intercalator/fluorescent-substance detection (claims 13–16 and beyond). Treat those as a secondary-source transcription, not an authoritative claim listing — pull the granted claims from USPTO PatentCenter (https://patentcenter.uspto.gov/) before you map a product against them. The point that matters strategically: none of them has been narrowed by IPR amendment or cancellation, so the patent owner asserts the original, broadest scope.

Estoppel landscape: essentially none against you — but that cuts both ways. Because no IPR ever reached FWD, no petitioner (and no privy) is subject to the § 315(e)(2) estoppel bar on grounds "raised or reasonably could have been raised." That means you face no inherited estoppel from anyone — the full § 102/§ 103 prior-art field is open, untilled, and unadjudicated. It also means there is no petitioner stipulation, no Sotera-type waiver, and no Board claim construction you can borrow. Every validity ground is a ground of first impression. Two structural constraints nevertheless apply to you directly: the § 315(b) one-year bar running from service of an infringement complaint, and the practical reality that a district court may stay its case behind an IPR (or refuse to).

Pattern signals: none to read. There is no repeat-petitioner pattern (no petitioner at all), no patent-owner PTAB-appeal track record (the owner has never had an FWD to appeal), and no aggregator in the chain. A patent granted in 2012 to a large diagnostics company (ARKRAY) that has gone ~14 years and its full pre-expiry life (to 2028-10-11) without a single AIA challenge is a mild signal that it has not been aggressively asserted in a way that provoked a big-budget validity attack — not a signal that it is invulnerable.

---

Recommended next steps

1. Confirm the negative, then move on. Verify the null PTAB result yourself at PTAB E2E / PatentCenter (https://patentcenter.uspto.gov/ and the PTAB public-information system at https://ptacts.uspto.gov/). If a petition has been filed but not yet indexed, it will surface there first. Absent that, plan on no PTAB proceeding to cite.

2. If you have been served, calendar the § 315(b) clock now. Because no prior FWD exists, an IPR you file would be a clean first challenge with no § 315(e)(2) estoppel baggage — but you lose the ability to file one year after service of the complaint.

3. Mine the patent's own background for candidate grounds. The specification itself identifies the art landscape you would build on: Patent Document 1 = JP 3727667B, and Non-Patent Documents 1–4 — Nucleic Acids Research Vol. 18, No. 19, 5908 (1990); Nucleic Acids Research Vol. 19, No. 5, 1151 (1991); Nucleic Acids Research Vol. 16, No. 20, 9775–9787 (1998); and Journal of Clinical Microbiology Vol. 39, No. 2, 485–493 (2001). The patent's own framing is useful to you: it concedes that whole-blood ratios of "about 1 to 10% by volume" were known, and argues novelty over the narrower 0.01–0.9% by volume / 0.01–1.8 g/L Hb window plus the optical-detection context. That admission is a ready-made § 102/§ 103 attack surface: the whole dispute is a numerical-range question, and numerical-range claims are often vulnerable to a Kustom Signals/criticality argument if you can show the recited range is a result-effective variable taught or suggested by the art. Note the specification's own counter-story — that at ≥1% by volume with albumin added "the PCR reaction solution turns into jelly" — which you should address, not ignore.

4. Ground your prior-art dates before you invest. All of the above references must be authenticated as printed publications publicly accessible before 2006-08-09. This is ordinary IPR homework, but there is no Board institution decision here to have done any of it for you.

5. If you do not want an IPR, the absence of any PTAB record is not itself a defense — it simply means validity will be fought on the district court's terms, with no § 315(e) estoppel, no FWD to distinguish, and no Board claim construction on the record.

Caveat on sourcing: this report is grounded in the structured ODP result, the Google Patents full text at https://patents.google.com/patent/US8148079/en (fetched 2026-09-24), and open web searches, which produced no PTAB or CAFC documents naming this patent. I did not locate any FWD, institution decision, settlement, or appeal to link, because none appears to exist. Where I have relied on a secondary transcription of the claims (drugpatentwatch.com), I have said so.

I'll research this patent's ownership records before building the report.

Ownership Analysis — US 8148079 B2

Patent: "Method of producing amplification product by PCR and usage thereof" · App. 12/294,304 · Filed 2007-08-07 · Priority 2006-08-09 · Issued 2012-04-03

Sourcing caveat up front: the USPTO Assignment Center (assignmentcenter.uspto.gov) was not directly queryable from this session, and no indexed mirror returned the reel/frame numbers or correspondent-of-record fields for this application. Everything below is grounded in the Google Patents legal-events record for US8148079B2 (fetched 2026-09-24), the full patent text, and third-party litigation/ownership databases. Reel and frame numbers and correspondent names are therefore reported as not retrieved rather than estimated — treat anything not cited to a numbered reel as unverified and re-check at the Assignment Center before relying on it.

Inventors

Pattern check: No unusual inventor-departure pattern. Majima was still obtaining US patents as an Arkray inventor four years after the '079 patent issued, which is the opposite of the pre-fire-sale tell (all inventors exiting the original assignee within 12 months of filing). Both inventors appear in the chain strictly as assignors to Arkray, consistent with ordinary employee invention-assignment obligations.

Original assignee

ARKRAY, Inc. (also styled ARKRAY, INC.), Kyoto, Japan — Yousuien-nai, 59 Gansuin-cho, Kamigyo-ku, Kyoto 602-0008.

• Status: Operating. Privately held Japanese company; no acquisition, no bankruptcy, no Chapter 7/11, no assignment of this patent ever recorded away from it.
• Business: Designs, manufactures, sells and services in-vitro diagnostic (IVD) instruments and reagents — blood glucose, HbA1c, urinalysis, clinical chemistry, and molecular/genetic testing. Corporate lineage traces to Kyoto Daiichi Kagaku, whose 1981 AUTO A1c HA-8110 was the first fully automated HbA1c analyzer. Note: the 2006-era name change to ARKRAY is not reflected as a recorded "Change of Name" conveyance against this patent (the change predates the 2006 priority date), so it does not appear as a link in this chain.
• Productization: The patent's own working examples were run on Arkray's own hardware — "Arkray system Ver.4" as the optical unit paired with an Eppendorf thermal cycler, citing Arkray's WO2005/118772 for the detection optics. That is internal productization of the detection platform the claims depend on, and Arkray's marketed real-time PCR genetic analyzers (e.g., the i-densy automated genetic analysis line) are consistent with commercial embodiment. The methods claims themselves (whole-blood fraction 0.1–0.9% v/v in the PCR reaction solution) are process claims that would be practiced with such a platform rather than sold as a separate article.

Assignment timeline

Two records exist, both inbound, inventor-to-employer, pre-issuance, and both naming the same parties. No post-issuance transfer of any kind (no assignment, security agreement, license, merger, or release) appears in the Google Patents legal-events record.

• 2008-09-24 (recorded) — Reel not retrieved (verify at Assignment Center)

  • Conveyance: Assignment (Assignment of Assignors' Interest)
  • Assignor: IZUMIZAWA, YUJI and MAJIMA, SATOSHI (joint)
  • Assignee: ARKRAY, INC.
  • Correspondent: not retrieved — the Assignment Center correspondent field is the single most valuable datum here and could not be read from this session; retrieve directly.
  • Context: initial capture of inventor rights by the employer during US national-phase entry of the PCT application.

• 2008-10-14 (recorded) — Reel not retrieved (verify at Assignment Center)

  • Conveyance: Assignment (Assignment of Assignors' Interest) — same assignor/assignee pair, recorded 20 days after the first
  • Assignor: IZUMIZAWA, YUJI and MAJIMA, SATOSHI
  • Assignee: ARKRAY, INC.
  • Correspondent: not retrieved — if the transcript shows the same attorney of record as the 2008-09-24 entry, this is a routine confirmatory/corrective re-recording; if it shows a different firm, that is an anomaly worth explaining before treating the chain as clean.
  • Context: corrective/confirmatory re-recording of the same employment assignment — the classic signature of a defect (missing inventor signature, defective notarization, or a filing error) being cured, not a transfer.

No further records. The chain terminates at ARKRAY, Inc. An "Adjusted expiration 2028-10-11" entry appears in Google Patents legal events; that is patent term adjustment under 35 U.S.C. § 154(b), not an ownership event, and should not be read as an assignment.

Timeline diagram

timeline
    title Ownership of US 8148079
    2006 : Priority date
    2007 : Application filed
    2008 : Inventors assign to Arkray
         : Same assignment recorded again
    2012 : Patent issued to Arkray
    2016 : Inventor Majima still filing at Arkray
    2028 : Adjusted expiration

NPE / troll-pattern signals

Verdict

Insufficient data — which in this case is a clean finding, not a gap in the interesting sense.

Justification: the only recorded assignments are the two 2008 inventor-to-employer recordings (2008-09-24 and 2008-10-14) conveying Izumizawa's and Majima's rights to ARKRAY, Inc., during national-phase entry. The second entry is a same-parties confirmatory re-recording, not a transfer. There is zero post-issuance assignment activity, no shell entity, no known asserter, no litigation naming the patent, and no bankruptcy — so the patent remains with its original operating-company owner, a Kyoto IVD manufacturer that built the Arkray detection hardware used in the patent's own examples. That falls squarely in the "only the original assignment" category, hence Insufficient data strictly speaking, but the substantive read is operating-company-held, non-asserted — the opposite of an NPE profile. The one unresolved item is the correspondent of record on both 2008 reels; retrieving it is the only step that could upgrade or further harden this verdict.

Verify at:

• USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search patent number 8148079; also https://assignment.uspto.gov/patent/index.html)
• Google Patents legal events — https://patents.google.com/patent/US8148079B2/en
• USPTO Patent Center / ODP — application 12/294,304

I'll search for the specific patent and its citation records.

I found the cited references list on Justia. Let me get the complete citation list and details.

Let me get details on the remaining cited U.S. and foreign references.

Prior Art Analysis — US 8,148,079 B2

1. Patent under analysis (verified identifiers, not auto-corrected)

Claim scope (from the record). Claim 1 is directed to a method of producing a PCR amplification product complementary to a target nucleic acid in a whole blood sample, wherein the ratio of whole blood in the PCR reaction solution is 0.01–0.9 % by volume. A parallel measure is expressed as ~0.01–1.8 g/L hemoglobin (abstract). Downstream method claims cover analysis of the amplification product by optical means and quantitative analysis of the target nucleic acid by Ct/number-of-cycles (see partial claim text at https://patents.justia.com/patent/[8148079](/patent/8148079)). I was able to retrieve only partial claim text (claims 1, 2 and 10). I could not verify the complete claim set, so the claim-level mappings below are reasoned estimates, not confirmed mappings.

Note on method and limits. I did not query USPTO PatentCenter directly; the data below is drawn from the USPTO-derived records mirrored on Google Patents and Justia. The patent lists nine patent citations ("Patent Citations (9)") plus foreign/granted documents and a substantial non-patent-literature list. Important caveat: a reference cited on the face of a patent is a document the examiner/applicant brought to the record — it is not an admission that it anticipates any claim. Anticipation under 35 U.S.C. § 102 requires that a single reference disclose every element of a claim. Several references below are § 103 (obviousness) or background references rather than true § 102 references.

---

2. Cited U.S. patent documents

(a) US 5,501,963 — the strongest single U.S. patent reference

• Full citation: US 5,501,963 A, "Amplification and detection of nucleic acids in blood samples," inventor Burkhardt; assignee Hoffmann-La Roche Inc. App. 08/118,534.
• Dates: filed 1993-09-11; granted 1996-03-26.
• Description: Methods for amplifying and detecting nucleic acids directly in blood-containing samples; discusses pre-treating blood (freezing/heating) to improve cell/virus lysis, and notes the denaturation step of the amplification reaction itself can serve that purpose.
• Potential § 102 relevance: In principle relevant to claim 1 (PCR amplification from a whole-blood sample) if it discloses a blood concentration within 0.01–0.9 % v/v. Based on the retrievable disclosure, it addresses blood-sample amplification generally and does not appear to teach the claimed narrow concentration window; more likely a § 103/background reference. URL: https://patents.google.com/patent/[US5501963A](/patent/US5501963A)/en

(b) US 2004/0091864 A1 — French et al.

• Full citation: US 2004/0091864 A1, "Hybridisation beacon and method of rapid sequence detection and discrimination," French et al.
• Date: published 2004-05-13.
• Description: Probe/hybridisation-beacon chemistry and real-time sequence detection/SNP discrimination (TaqMan, molecular beacons, hybridisation probes, Scorpions).
• Potential § 102 relevance: Bears on the detection/analysis claims (process of detecting the amplification product by optical means / real-time fluorescence detection), not on the whole-blood-ratio limitation. Alone it cannot anticipate claim 1. URL: https://patents.google.com/patent/US20040091864

(c) US 2005/0260606 A1 — Kermekchiev et al.

• Full citation: US 2005/0260606 A1, Kermekchiev et al.
• Date: published 2005-11-24.
• Description: DNA polymerases / reaction conditions for tolerating PCR inhibitors (i.e., amplification in "dirty" samples). I could not independently verify the exact title text from the retrieved snippets — treat the description as inferred from the citation context, not confirmed.
• Potential § 102 relevance: Relates to the general problem of PCR inhibition in crude biological samples; relevant to the "suppression of PCR inhibition / amplification efficiency" rationale of claim 1, but does not disclose the 0.01–0.9 % v/v whole-blood range. § 103-type reference.

(d) US 2006/0216720 A1 — Carvalho et al.

• Full citation: US 2006/0216720 A1, Carvalho et al.
• Date: published 2006-09-28.
• Description: Nucleic-acid amplification/detection in blood-type samples (inferred from citation grouping; title not independently confirmed).
• Potential § 102 relevance: Same class as (a)/(c); relevant to the general step of amplifying/detecting nucleic acid from blood, but no evidence of the claimed concentration window. § 103/background.

---

3. Cited foreign/granted patent documents

---

4. Most relevant prior art is largely the cited non-patent literature

The face of the patent and the supplementary European search report (EP 07792129.4) cite a body of non-patent literature that is, in substance, the closest art to the core claim limitation (direct PCR from whole blood):

• Mercier et al., "Direct PCR from whole blood, without DNA extraction," Nucleic Acids Research 18(19):5908 (1990) — Non-Patent Document 1 of the specification. Directly on point for claim 1 (PCR on whole blood without pretreatment).
• "PCR-based diagnosis in the presence of 8 % (v/v) blood," Nucleic Acids Research 19(5):1151 (1991) — Non-Patent Document 2. Discloses a higher blood concentration (8 % v/v), i.e., outside the claimed range.
• Pääbo et al., Nucleic Acids Research 16(20):9775–9787 (listed in the patent as "(1998)") — Non-Patent Document 3. Note: the year appears in the record as 1998; the actual Pääbo publication is 1989. Per the instruction to interpret identifiers literally, I flag the 1998 date as it appears and do not silently correct it.
• Al-Soud et al., Journal of Clinical Microbiology 39(2):485–493 (2001) — Non-Patent Document 4 (PCR-inhibitory components in blood cells).
• Additional references of record: Al-Soud et al., J. Microbiol. Methods 32(3):217–224 (1998); Al-Soud et al., Appl. Environ. Microbiol. 64(10):3748–3753 (1998); Al-Soud et al., J. Clin. Microbiol. 38:4463–4470 (2000); Burckhardt, "Amplification of DNA from Whole Blood," PCR Methods and Applications 3(4):239–243 (1994); Wu et al., Clinical Chemistry 39(4):737 (1993); Panaccio et al., "FoLT PCR: A Simple PCR Protocol for Amplifying DNA Directly from Whole Blood," BioTechniques 14(2):238–243 (1993).

These references collectively establish that direct PCR from (diluted) whole blood was known. Their disclosure, however, generally concerns higher blood fractions or crude-sample tolerance, not the specific 0.01–0.9 % v/v window discovered by the patentees to permit optical monitoring — which is the crux of the claimed invention.

---

5. Bottom line

Most relevant prior art, ranked:

1. JP 3727667 B — the closest patent reference; discloses whole-blood PCR at 1–10 % v/v. Relevant to claim 1 but as a § 103 reference (higher, non-overlapping range).
2. US 5,501,963 (Burkhardt / Hoffmann-La Roche) — blood-sample amplification/detection; § 102/§ 103 candidate for claim 1 depending on whether it discloses the claimed concentration.
3. Mercier 1990 / Panaccio 1993 / Burckhardt 1994 / Wu 1993 (NPL) — direct whole-blood PCR; § 102 candidates for the "whole blood by PCR" element, but no evidence they disclose the 0.01–0.9 % v/v limitation.
4. US 2004/0091864 (French), WO 2005/118772, and the Al-Soud body of work — relevant to the detection/optical-analysis and PCR-inhibition aspects, not to the ratio limitation.

Anticipation assessment: No single cited reference that I verified discloses all elements of claim 1 (whole-blood PCR at 0.01–0.9 % v/v in combination with optical monitoring). The cited art is therefore best characterized as § 103 obviousness material (notably the jump from the known 1–10 % v/v range down to 0.01–0.9 % v/v) rather than true § 102 anticipation, unless a reference discloses the specific concentration limitation — which would require full-text verification of each document.

---

6. Explicit uncertainties / limits

• Only partial claim text was retrievable (claims 1, 2, 10); claim-by-claim § 102 mapping is therefore indicative, not authoritative. The complete claim set should be pulled from USPTO PatentCenter for US 12/294,304.
• Titles/disclosures of EP 0 751 226, JP 6-277062, JP 9-187277, US 2005/0260606, and US 2006/0216720 were not independently verified; I have flagged inferred descriptions rather than asserted them as fact.
• A citation on the face of a patent is not proof of anticipation; the references above reflect what is "of record," and the examiner's actual rejections (if any) would be documented in the file wrapper.
• Data drawn from mirrored USPTO records (Google Patents, Justia); the authoritative source remains USPTO PatentCenter / the official file history.

I'll ground the prior-art references cited in this patent before building the §103 analysis. Let me run targeted searches.

Now let me characterize the remaining prior art references and try to locate the granted claims.

Obviousness Analysis — U.S. Patent No. 8,148,079 under 35 U.S.C. § 103

Patent: U.S. 8,148,079 B2, "Method of producing amplification product by PCR and usage thereof"
App. No.: 12/294,304 · Filed: 2007-08-07 · Priority: 2006-08-09 · Granted: 2012-04-03
Assignee: Arkray, Inc. · Inventors: Yuji Izumizawa, Satoshi Majima
Source of record: https://patents.google.com/patent/[US8148079](/patent/US8148079)/en

---

0. Scope caveat (read first)

The authoritative full text supplied for this page does not include a claims section — the Google Patents capture ends inside the Example 4 discussion. My claim-1 reconstruction below is therefore drawn from the Abstract and the "Disclosure of Invention" summary, which disagree with each other and with the detailed description:

The 0.1 vs. 0.01 lower bound and 1.5 vs. 1.8 g/L upper bound are material to every §103 range argument below, and the description contains an apparent typographical omission ("in the range of 0.1 to g/L"). I cannot tell from the provided text which boundary the granted claims actually recite. If you can supply the claim set, the range-criticality analysis in §5 should be re-run against the literal language.

---

1. The claimed subject matter, reduced to its inventive core

Stripped to essentials, claim 1 (as reconstructed) requires:

1. Producing, by PCR, an amplification product complementary to a target nucleic acid in a whole blood sample;
2. wherein the whole blood fraction in the PCR reaction solution is 0.01 (or 0.1) to 0.9 % by volume, or equivalently 0.01 to 1.8 g/L in hemoglobin terms;
3. implicitly, without a purification/pretreatment of the sample and without aftertreatment of the reaction solution (expressly stated in the Summary as the point of novelty).

Dependent/aspect claims evidently cover: added albumin (0.01–5 wt%, pref. 0.2–0.8 wt%); a pre-PCR heat treatment (≥80 °C, 30 s–15 min, on a diluted sample of 0.5–5 % v/v blood); and real-time/optical detection by intercalator, TaqMan®, hybridization, or cycling-probe chemistry.

So the entire asserted advance over the art is one numeric limitation — reduce the whole-blood fraction below ~1 % — plus the recognition that this makes optical (not electrophoretic) readout feasible.

---

2. The prior art of record and what each reference teaches

Sister-application data point: Arkray's later PCT filing WO 2008/066162 A1 (CYP2C19 amplification) recites in its claim 16 that "the ratio of the whole blood sample added to the reaction solution is 0.1 to 0.5 % by volume." That is Arkray's own post-priority characterization of the operative range, and it brackets the claimed window — useful context when assessing whether the range was "inventive" or merely the applicational norm.

---

3. Ground of rejection #1 (primary): JP3727667B2 + NPD-2 + NPD-3/NPD-4 + real-time PCR art

Proposed combination: JP3727667B2 as the base (blood-sample PCR at ~1–10 % v/v), in view of Panaccio & Lew (NPD-2) and/or Mercier (NPD-1) for the "untreated whole blood / inhibition-by-blood" teaching, in further view of Pääbo (NPD-3) and JCM 2001 (NPD-4) for albumin as a known inhibitor-neutralizing additive, and in further view of the real-time/optical PCR art (Higuchi 1992; Heid 1996; Arkray's own WO 2005/118772) for the intended fluorescence-monitoring readout.

Motivation to combine, articulated as a POSITA would have articulated it in 2006:

1. The art itself names the problem. NPD-2 states plainly that blood is a PCR inhibitor; the '079 specification concedes the same. A POSITA confronting inhibition has a small, well-known toolkit: purify the sample, add an inhibitor-neutralizing additive, or dilute.
2. Dilution is the paradigm remedy. The record (and general PCR practice) treats dilution as the standard first-line countermeasure for sample-borne inhibitors. Reducing the sample fraction is the single most predictable, monotonic way to reduce both inhibitor load and heat-denatured protein/turbidity.
3. Albumin addition is expressly known. NPD-3 goes further than mere enzyme-protection: it teaches that BSA prevents inhibition caused by heme compounds, i.e., it identifies albumin as a blood/heme-directed rescue agent. A POSITA diluting whole blood and wanting additional margin would obviously add the known additive.
4. The readout dictates the target. The claimed point is not PCR-with-blood (old) but optical PCR-with-blood. The real-time PCR art was mature by 2006 and its practitioners knew that turbidity/precipitate that is invisible in gel electrophoresis scatters excitation/emission light and corrupts fluorescence. Wanting Ct-value monitoring therefore supplies an independent, articulated motivation to drive the sample fraction low enough that the reaction stays clear.
5. The work to be done is a titration. Figure 1 of the patent is, in substance, a routine optimization curve: blood fraction on the x-axis, fluorescence on the y-axis. Nothing in the reference set suggests a new reagent, a new chemistry, or an unpredictable mechanism — only the selection of a numeric value for one result-effective variable.

Under KSR Int'l Co. v. Teleflex, Inc., 550 U.S. 398 (2007), where a design need is identified and there are "a finite number of identified, predictable solutions," pursuit of those solutions is obvious. Here the "need" (optically readable blood PCR) is identified by the real-time art and by the patent's own background, and the "solution set" is a one-dimensional continuum of sample concentrations with a known direction of effect.

---

4. Ground of rejection #2: NPD-1 + NPD-2 + NPD-3 (all-printed-publication combination)

If JP3727667B2's Japanese-language disclosure is treated as weak evidence of the specific 1–10 % figure, the same prima facie case is available purely from the printed publications:

• Mercier 1990 (NPD-1) — direct PCR from whole blood with no extraction; establishes the concept and presumably an operant blood fraction on the order of 1 %.
• Panaccio & Lew 1991 (NPD-2) — pushes to 8 % v/v and states the inhibition problem explicitly.
• Pääbo 1988 (NPD-3) — albumin overcomes heme-mediated PCR inhibition.

The same reasoning applies: the art is crowded above 1 % and is unanimous that blood inhibits the reaction; the only move left to a POSITA seeking a non-turbid, optically monitorable reaction is downward in concentration, with albumin as the known adjunct.

---

5. Ground of rejection #3: "obvious to try" and range-optimization doctrine

Even without an explicit combination motivation, the range limitation is vulnerable on its own:

• In re Aller, 220 F.2d 454 (CCPA 1955): discovering the optimum or workable range of a result-effective variable by routine experimentation is not inventive. The whole-blood fraction is quintessentially a result-effective variable.
• In re Woodruff, 919 F.2d 1575 (Fed. Cir. 1990) and In re Peterson, 315 F.3d 1325 (Fed. Cir. 2003): adjacent/overlapping ranges are prima facie obvious absent a showing of criticality or unexpected results. The claimed 0.9 % upper bound sits immediately adjacent to the art's 1 % lower bound.
• The hemoglobin-content limitation (0.01–1.8 g/L) is the same concentration expressed in different units. Re-expressing a disclosed or obvious volume fraction as an equivalent hemoglobin mass concentration adds no new technical element and is, standing alone, obvious. (It is also, on this record, doubly suspect under §112 — the 1.5 vs. 1.8 g/L discrepancy and the "0.1 to g/L" omission — though that is a separate ground.)

---

6. Likely dependent claims and their §103 posture

---

7. The applicant's best rebuttals, and how they cut

(a) Teaching away / "maximize the blood." The direct-PCR-from-blood literature (Mercier; Panaccio) is premised on using as much untreated blood as possible to avoid analyte loss. A POSITA could argue the art led away from sub-1 % dilutions because dilution reduces target copy number and risks false negatives (In re Gurley, 27 F.3d 551 (Fed. Cir. 1994)). Counter: the reference set never disparages low blood fractions, and nothing in it forecloses dilution; a mere preference for a different value is not a teaching away absent a sufficiently strong discouragement.

(b) Criticality / unexpected results. This is the applicant's strongest card. Figure 1 shows a sharp operational cliff — no measurable fluorescence at ≥2 % v/v, adequate signal at ≤0.5 % — and the examples report heat-treatment gains of 3.2–5.3× in effective template. The patent also asserts an inoperability that the art did not appreciate: at the art's own 1 %+ whole-blood concentration, adding albumin turns the reaction solution to jelly, defeating optical detection. If framed as a newly discovered criticality in a range the prior art used only for gel-based readout, this is a credible non-obviousness position. Counter (KSR): criticality must be shown to be unexpected; a monotonic "less blood → less turbidity → better optics" trend is precisely what a POSITA would have predicted once optical readout was the goal. Applicant bears the burden (In re Soni, 54 F.3d 746 (Fed. Cir. 1995)).

(c) Commensurate scope. Even accepting the Fig. 1 data, the claimed 0.01–0.9 % range is far broader than the demonstrated 0.5 %-and-below window, and the 0.9 % upper bound is not shown to be a critical boundary (the data cluster the transition between ~0.5 % and 2 %). Under the commensurate-in-scope requirement, a narrow showing cannot rescue a broad range.

(d) What is not a winning argument. The patent's "jelly" observation is expressly tied to the prior art's ≥1 % + albumin combination. It therefore argues against the old range, not in favor of the claimed sub-0.9 % range — and may be inadmissible as an admission that the sub-0.9 % + albumin combination was an obvious thing to try.

---

8. Conclusion

Prima facie case for §103 rejection: strong.

The claimed invention differs from the art of record by a single numeric boundary — placing the whole-blood fraction below ~1 % — a variable the art already recognized as the source of PCR inhibition (NPD-2), on a sample type the art already used untreated (NPD-1, JP3727667B2), with an additive the art already used to neutralize blood-borne inhibitors (NPD-3, NPD-4), for a readout modality (optical/real-time PCR) already conventional. The direction of the effect is monotonic, the solution space is one-dimensional, and the assignee's own later filing (WO 2008/066162, claim 16) claims 0.1–0.5 % as the operative window. Under KSR, In re Aller, and In re Woodruff/Peterson, each independent claim as reconstructed is prima facie obvious.

The rejection should nonetheless be regarded as contestable, and may fail, on two grounds the examiner would have to meet head-on:

1. Criticality / unexpected results — the asserted non-obvious finding that the previously acceptable 1–10 % range is inoperable under optical detection (precipitate/turbidity; "jelly" with albumin) may support patentability if applicant demonstrates the effect is unexpectedly sharp at the claimed boundary rather than a predictable continuation of a monotonic trend (Figs. 1–3). Expect a Rule 132 declaration on this point.
2. Non-commensurate scope — if the claim's lower bound is the Abstract's 0.1 % rather than the description's 0.01 %, the range narrows toward the demonstrated data and the obviousness case weakens at the margin (though the adjacent-range doctrine still applies).

Residual uncertainties in this analysis (flagged, not resolved):

• The granted claim language was not available in the supplied text; the above is keyed to the Abstract/Summary and must be re-verified.
• NPD-4 (JCM 39(2):485–493, 2001) could not be independently verified in this session; it is treated per the patent's own characterization.
• JP3727667B2's full text was not retrieved; its title, assignee, priority and the "1–10 % v/v" teaching are taken from the source page's citation table and the '079 background, respectively.
• The 0.1/0.01 % and 1.5/1.8 g/L inconsistencies between the Abstract, Summary and description are internal contradictions in the authoritative text that materially affect any range-based §103 holding.